Skip to content
Screener

Price / book at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.1×+0.2×
EyePoint, Inc. logo
EyePoint, Inc.EYPT
7.2×+4.6×
KLR
Kalaris TherapeuticsKLRS
1.9×
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
1.1×+0.7×
HRO
HarrowHROW
104.1×+80.7×
PVL
Palvella TherapeuticsPVLA
7.7×+2.0×

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.84B+570%
Enterprise value$2.73B+608%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

Based on the most recent quarter.

The source filing: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211951

FAQ

What is Kodiak Sciences Inc's price / book?
Kodiak Sciences Inc (KOD) reported price / book of 20.8× in Q1 2026.
How has Kodiak Sciences Inc's price / book changed year-over-year?
Kodiak Sciences Inc's price / book increased by 1430.7% year-over-year, from 1.4× to 20.8×.
What is the long-term trend for Kodiak Sciences Inc's price / book?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's price / book has grown at a 4.2% compound annual growth rate (CAGR), from 8.8× to 10.8×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Kodiak Sciences Inc's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude